Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 Randomized Clinical Trial

Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 Randomized Clinical Trial

Abstract Introduction Evolocumab, a fully human proprotein convertase/subtilisin kexin type 9 inhibitor antibody, significantly lowers low-density lipoprotein cholesterol (LDL-C) in patients with type 2 diabetes mellitus and hyperlipidemia and mixed dyslipidemia. This 12-week study evaluated the eff...

Full description

Bibliographic Details
Main Authors: Hong Tan, Weimin Li, Zhouqing Huang, Yajun Han, Xuecheng Huang, Dongye Li, Xiaochun Xing, Maria Laura Monsalvo, You Wu, Jackie Mao, Lily Xin, Jiyan Chen, HUA TUO study investigators
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-02-01
Series:Cardiology and Therapy
Subjects:
Evolocumab
Hypercholesterolemia
Mixed dyslipidemia
LDL cholesterol
PCSK9
Hyperlipidemia
Online Access:https://doi.org/10.1007/s40119-023-00304-x

Internet

https://doi.org/10.1007/s40119-023-00304-x

Similar Items